Gout in black South Africans: a clinical and genetic study

Bilkish Cassim, Girish M Mody, Vijay K Deenadayalu, Michael G Hammond

Abstract
Objective—To define the clinical characteristics of gout and determine if there were any genetic associations with gout in black South Africans.

Methods—The records of 107 patients with gout seen over a five year period were retrospectively analysed. The HLA class I and class II antigens were studied in a prospective survey of 46 patients.

Results—The male to female ratio was 6:6:1. The diagnosis of gout was based on identification of monosodium urate crystals from the synovial fluid, synovial tissue or tophaceous material in 62 patients (58%) and on clinical criteria in the remaining 45 patients (42%). The mode of presentation was monoarthritis in 40 patients (37-4%), pauciarticular in 30 (28%) and polyarthritis in 37 (34-6%). The joints which were most frequently involved were the knee in 91 patients (85%), the first metatarsophalangeal in 80 (74-8%) and the ankle in 66 (61-7%). A secondary cause was identified in 52 patients (48-6%) (diuretic therapy in 48 patients and chronic renal impairment in four); 55 patients (51-4%) had primary gout. The genetic study showed an increased frequency of HLA-B14 in patients with primary gout compared with controls.

Conclusions—Gout is more common in black Africans than previously recognised and frequently presents with involvement of more than one joint. There was an increased frequency of HLA-B14 in patients with primary gout but the clinical significance of this is uncertain.


Genetic and environmental factors influence the prevalence of hyperuricaemia and gout in various ethnic groups1–3 and urban and rural populations.4,5 Gout was reported to be uncommon in black Africans6–9 and this was confirmed in a previous survey from our hospital.10 More recent studies have reported a greater prevalence of gout in black Africans11,12 and a higher prevalence has also been reported in a black American population.13 Although a genetic predisposition to gout is well recognised, no association with HLA antigens has been reported.14,15 In view of the relative rarity of gout in black Africans, we studied the HLA class I and class II antigens to determine if these antigens were associated with the development of gout. In addition, we defined the clinical characteristics of gout in black Africans.

Patients and methods
The King Edward VIII Hospital is a 2000 bed State funded public hospital attached to the University of Natal Medical School in Durban, South Africa. A computer assisted search of the inpatient records over a five year period from 1984 to 1989 was undertaken and the results of synovial fluid analysis were reviewed to identify patients with gout. Patients were considered to have gout if monosodium urate crystals were identified in synovial fluid, synovial tissue or tophi or if they fulfilled the American Rheumatism Association (ARA) clinical criteria for gout.16 There were 107 patients who fulfilled these criteria. Their clinical records were reviewed and the age of onset, duration of disease, history of alcohol intake, mode of presentation, criteria for diagnosis, presence or absence of associated diseases and available biochemical data were recorded. The clinical characteristics of the subgroups of patients were compared using Student’s t test for equal and unequal variances. HLA class I and class II antigens were determined in a prospective study of 46 patients with gout. HLA-A, B and C were identified using a two stage lymphocytotoxicity test17 and 180 antisera. HLA-DR and DQ were defined with 120 antisera on B cell enriched lymphocyte suspensions prepared by the use of straws packed with nylon wool.18 HLA-A, B and C were determined in all 46 patients (23 primary and 23 secondary gout), HLA-DR in 36 patients (20 primary and 16 secondary gout) and HLA-DQ in 34 patients (18 primary and 16 secondary gout). The control group comprised blood donors and staff of the Natal Institute of Immunology. HLA-A, B and C were tested in 2366 controls, HLA-DR in 534 and HLA-DQ in 517. The differences in frequency of the various antigens between patients and controls were tested for significance by means of the χ2 test and Fisher’s exact test (in the case of small cell sizes). The resulting probabilities were multiplied by the number of HLA specificities tested to obtain the corrected values.

Results
The mean age at onset of disease was 50.5 (11.5) years (range 32–85 years) and the mean
duration of gout was 3·4 (4·4) years (range one month to 23 years). The male to female ratio was 6·6:1. Females were significantly older at onset of disease than males (57 years compared with 49·3 years (p < 0·01)) and secondary gout was more frequent in females (78·6%) than in males (44%) (p < 0·05). However, there was no significant difference in the duration of disease, mode of presentation or pattern of joint involvement between males and females (table 1).

The diagnosis of gout was based on identification of monosodium urate crystals in 62 patients (58%). The crystals were identified from the synovial fluid in 53 patients, mostly from the knee (43 patients), and from synovial biopsy tissue (three), and tophi (six). A clinical diagnosis of gout was made in the remaining 45 patients (42%) who fulfilled the ARA clinical criteria for gout. A history of recurrent acute attacks was obtained in 92 patients (86%) and 39 (36%) had suspected tophi. Tophi were present at the elbows in 63% of patients, ears in 30%, hands in 22%, and feet in 22%. There was no difference in the frequency or site of tophi in patients with primary or secondary gout. Hyperuricaemia at the time of presentation was noted in 103 patients (96%).

The pattern of presentation was monoarthritis in 40 (37·4%), pauciarticular in 30 (28%) and polyarthritis in 37 (34·6%). The joints most frequently involved were the knee (91 patients (85%)), first metatarsophalangeal (80 (74·8%)) and ankle (66 (61·7%)).

A secondary cause was identified in 52 patients (48·6%)—48 receiving diuretic therapy for either hypertension (43) or cardiomyopathy (five) and four who had chronic renal impairment alone. The four patients with chronic renal impairment included three who were over 60 years and one who was 49 years old. Two of these patients had hypertension alone, one had hypertension and diabetes, and the remaining patient did not have any coexisting disease. Urinary uric acid excretion was normal in the two patients in whom the test was performed. Renal impairment (increased blood concentrations of urea and creatinine) was also present in 14 of the 43 patients with hypertension who were receiving diuretic therapy. The possible contribution of non-steroidal anti-inflammatory drugs (NSAID) to renal impairment could not be determined from a review of the hospital records.

One patient had chronic myeloid leukaemia and another pulmonary tuberculosis; however, the diagnosis of gout preceded that of the two other conditions and these patients were classified as having primary gout.

A history of alcohol intake was recorded in 92 patients. Seventy three patients (79%) gave a history of alcohol intake, but details as to the type and amount of alcohol consumed were not available.

Table 2 compares patients with primary gout and those with secondary gout. An older age at onset (53 years) was noted in secondary gout, compared with 48·3 years in primary gout (p = 0·05). Secondary gout was more common in females (78·6%) compared with males (44%) (p < 0·05). There was no significant difference in duration of disease, mode of presentation or pattern of joint involvement between the primary and secondary groups.

In the HLA study there was a significant increase in the frequencies of the A28, B14, Cw1, DR8 and DQw3 antigens in patients with primary gout and of A28, B17 and Cw3 antigens in patients with secondary gout compared with control subjects (table 3). After correction for the number of antigens tested, only B14 remained significantly increased in patients with primary gout (p(exact) = 0·005). Further correction for the two groups of patients also showed a significant increase for B14 (p < 0·01). Comparing primary and secondary gout (table 3), the B14 antigen was present in 26·1% of patients with primary gout and 4·4% of patients with secondary gout (χ² = 4·21; p(exact) = 0·048), whilst the B70 antigen was present in 43% of patients with secondary gout and 8·7% of patients with primary gout (χ² = 7·22; p(exact) = 0·0083). Corrected p values did not reach statistical significance.

Discussion

Gout has been recognised as an uncommon disease in black Africans. Small numbers of patients with gout were reported from

Table 1 Comparisons between male and female patients

<table>
<thead>
<tr>
<th></th>
<th>Male (n = 93)</th>
<th>Female (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age at onset (yr)</td>
<td>49·3 (12·4)</td>
<td>56·9 (9·5)</td>
</tr>
<tr>
<td>Duration of disease (yr)</td>
<td>3·4 (4·5)</td>
<td>3·2 (3·9)</td>
</tr>
<tr>
<td>Mode of presentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monoarticular (%)</td>
<td>38</td>
<td>36</td>
</tr>
<tr>
<td>Pauciarticular (%)</td>
<td>28</td>
<td>29</td>
</tr>
<tr>
<td>Polyarticular (%)</td>
<td>32</td>
<td>36</td>
</tr>
<tr>
<td>Secondary gout (%)</td>
<td>44</td>
<td>78·6</td>
</tr>
<tr>
<td>Joints involved</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knee (%)</td>
<td>87</td>
<td>71</td>
</tr>
<tr>
<td>Metatarsophalangeal (%)</td>
<td>77</td>
<td>77</td>
</tr>
</tbody>
</table>

Table 2 Comparisons between primary and secondary gout

<table>
<thead>
<tr>
<th></th>
<th>Primary (n = 55)</th>
<th>Secondary (n = 52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age at onset (yr)</td>
<td>49·3 (12·3)</td>
<td>57 (11·4)</td>
</tr>
<tr>
<td>Duration of disease (yr)</td>
<td>3·6 (4·6)</td>
<td>3·2 (4·3)</td>
</tr>
<tr>
<td>Mode of presentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monoarticular (%)</td>
<td>42</td>
<td>33</td>
</tr>
<tr>
<td>Pauciarticular (%)</td>
<td>20</td>
<td>36</td>
</tr>
<tr>
<td>Polyarticular (%)</td>
<td>38</td>
<td>32</td>
</tr>
<tr>
<td>Secondary gout (%)</td>
<td>17·3:1</td>
<td>2·7:1</td>
</tr>
<tr>
<td>Joints involved</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knee (%)</td>
<td>84</td>
<td>87</td>
</tr>
<tr>
<td>Metatarsophalangeal (%)</td>
<td>73</td>
<td>77</td>
</tr>
</tbody>
</table>

Table 3 Comparison of HLA frequencies in control subjects and patients with primary or secondary gout

<table>
<thead>
<tr>
<th>HLA Antigen</th>
<th>Controls (n = 2366)</th>
<th>Primary (n = 55)</th>
<th>Secondary (n = 52)</th>
<th>p(exact)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>A28</td>
<td>21·1</td>
<td>39·1*</td>
<td>43·5**</td>
<td>0·048</td>
</tr>
<tr>
<td>B14</td>
<td>6·1</td>
<td>26·1***</td>
<td>4·4</td>
<td>0·0083</td>
</tr>
<tr>
<td>B70</td>
<td>28·1</td>
<td>8·7*</td>
<td>43·5</td>
<td></td>
</tr>
<tr>
<td>Cw1</td>
<td>0·5</td>
<td>4·3*</td>
<td>0·0</td>
<td></td>
</tr>
<tr>
<td>Cw3</td>
<td>12·1</td>
<td>13·0</td>
<td>30·4**</td>
<td></td>
</tr>
<tr>
<td>DR8</td>
<td>4·7</td>
<td>15·0*</td>
<td>0·0</td>
<td></td>
</tr>
<tr>
<td>DQw3</td>
<td>31·9</td>
<td>55·6*</td>
<td>37·5</td>
<td></td>
</tr>
</tbody>
</table>

Comparisons with control: *p < 0·05; **p < 0·01; ***p < 0·0001. †Comparisons between primary and secondary gout.
Gout in black South Africans: a clinical and genetic study

Uganda, Kenya, Zaire and Zimbabwe. During epidemiological surveys in South Africa a few cases of hyperuricaemia were detected but no patients with gout were seen. Lowental and Dymond reported 11 patients with gout seen over a 38 month period in Johannesburg and 19 patients with gout who were seen over a five year period were reported from our hospital. However, a recent study from Brazzaville showed that gout was the most frequent cause of inflammatory arthritis and was detected in 60 patients, while Mijiyawa et al reported 71 patients with gout from Togo. Our study of 107 patients represents the largest series of gout in black Africans and confirms an increasing prevalence, which may be attributable to genetic or environmental factors and to a greater awareness of the disease and increased detection as a result of synovial fluid analysis for monosodium urate crystals in patients with pauciarticular polyarthritis.

The mean age of onset was 50-5 (11-5) years which is older than that found in a British series of 354 patients. This could be explained by the greater prevalence of secondary gout in our patients. We found a female to male ratio of 6-6:1 and the age of onset was greater in females, in agreement with findings by Macfarlane and Dieppe. Secondary gout was present in 48-6% of our patients, compared with 8-5% in the British series. Females were more likely than men to have secondary gout (78-6% compared with 44%). A history of diuretic treatment was obtained in 71-4% of females and 40% of males. This compares to the finding of Macfarlane and Dieppe that all the females and 33% of males in a group of patients with gout were receiving diuretics. In addition, 14 of their 51 patients with diuretic induced gout had renal impairment which may have been an additional risk factor for the gout. Scott and Higgins found that all their 15 patients with diuretic induced gout had an additional risk factor, either renal impairment or polycystic kidneys.

Gout secondary to renal disease is rare, but Vecchio and Emmerson reported 12 patients with primary renal disease, other than chronic lead nephropathy and polycystic kidneys, at the time of or preceding the first attack of gout. All these patients had a reduced fractional urate clearance which may contribute to the development of hyperuricaemia and gout. A reduced fractional urate clearance has also been reported in a series of 21 patients with precocious familial gout and 14 patients with hereditary nephropathy with hyperuricaemia and gout. We found four patients who had gout which could be attributed to primary renal disease. None of these patients had a family history of renal disease or gout and the urinary uric excretion was normal in the two patients in whom the test was performed. The possible contribution of NSAIDs to renal impairment could not, however, be excluded in this retrospective analysis.

The majority of our patients (62-6%) presented with involvement of more than one joint compared with only 11% of patients in the British series. This may be explained in part by the inclusion of outpatients in the British series, whereas we studied mainly hospital inpatients who are likely to have more severe disease; also, older female patients were included in our series. Lawry et al reported that polyarticular gout reflected chronicity associated with poor patient understanding, poor patient compliance and suboptimal physician management. In addition, serum concentrations of monosodium urate may be normal in polyarticular gout. Raddatz et al reported that 19 of their 41 patients with polyarticular gout were misdiagnosed initially and we also encountered similar patients.

Previous studies of 66 white patients with gout and 22 males with gout and 105 of their first degree relatives did not detect any significant difference in the frequency of HLA compared with controls. We found a significant increase in the frequency of HLA-B14 in patients with primary gout but the clinical significance of this finding is uncertain and may be the result of a sample bias. An increased prevalence of HLA-B14 antigen has also been reported in black South Africans with insulin dependent diabetes and Graves' disease but none of our B14 positive patients had either of these diseases.

Conclusions

In this hospital based study we confirm that gout is more common in black Africans than previously recorded. This may be the result of environmental factors associated with increasing urbanization in a country under-going socio-economic and political change, genetic factors, or an increased awareness of the disease. On the basis of this study we suggest that, among black Africans, gout must be included in the differential diagnosis of pauciarticular or polyarthritis in males and postmenopausal females. A weak association with HLA-B14 has been noted in patients with primary gout and further studies are needed to determine if this is of any clinical significance.


Gout in black South Africans: a clinical and genetic study.

B Cassim, G M Mody, V K Deenadayalu and M G Hammond

doi: 10.1136/ard.53.11.759

Updated information and services can be found at:
http://ard.bmj.com/content/53/11/759

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/